Skip to main content

IBM pitched Watson as a revolution in cancer care. It’s nowhere close

Noted: Pilar Ossorio, a professor of law and bioethics at University of Wisconsin Law School, said Watson should be subject to tighter regulation because of its role in treating patients. “As an ethical matter, and as a scientific matter, you should have to prove that there’s safety and efficacy before you can just go do this,” she said.